Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma, and ATRT

Sponsor: Medical University of Vienna

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT01356290

Provider View

This study is exploring a new treatment option for children with recurring brain tumors like medulloblastoma, ependymoma, and ATRT. The treatment combines several medications to target tumor growth and aims to improve survival while maintaining quality of life.

Patient Parameters

Program Overview

Children with recurring brain tumors such as medulloblastoma, ependymoma, and ATRT often have limited treatment options and poor outcomes with standard therapies like chemotherapy and radiation. This study is testing a new approach called antiangiogenic therapy, which involves using a combination of medications to slow down tumor growth by targeting the blood vessels that supply the tumor. The treatment includes a biweekly infusion of bevacizumab and five oral drugs, along with additional medications given directly into the spinal fluid. The goal is to find out if this combination can help children live longer and maintain a good quality of life. Researchers will also look at how well the treatment works, how long it keeps the cancer from getting worse, and any side effects.

Eligibility Criteria

Inclusion Criteria

  • Children and young adults under 20 years old with recurring or worsening medulloblastoma, ependymoma, or ATRT.
  • Must have a confirmed diagnosis of one of these brain tumors.
  • Normal organ and bone marrow function, with specific blood test results within acceptable limits.
  • Able to perform daily activities with a performance status score of 50 or higher.
  • Written consent from the patient or their parents to participate in the study.

Exclusion Criteria

  • Active infections.
  • Dependency on a VP shunt (a device used to relieve pressure on the brain).
  • Pregnant or breastfeeding individuals.
  • Recent treatment with standard chemotherapy, antiangiogenic drugs, or full radiation for the current tumor recurrence.
  • Allergies to any of the study medications.
  • Active stomach ulcers.
  • Uncontrolled heart conditions or high blood pressure.
  • Need for major surgery during the study.
  • Any condition that makes the study treatment unsafe or increases the risk of complications.
  • Unhealed surgical wounds or bone fractures.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.